Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systematic assessment of decision-analytic models for chronic myeloid leukemia.
Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U. Rochau U, et al. Among authors: gastl g. Appl Health Econ Health Policy. 2014 Apr;12(2):103-15. doi: 10.1007/s40258-013-0071-8. Appl Health Econ Health Policy. 2014. PMID: 24385259 Review.
Medical decision analysis for first-line therapy of chronic myeloid leukemia.
Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, Brixner D, Radich J, Gastl G, Siebert U. Rochau U, et al. Among authors: gastl g. Leuk Lymphoma. 2014 Aug;55(8):1758-67. doi: 10.3109/10428194.2013.858149. Epub 2014 Feb 6. Leuk Lymphoma. 2014. PMID: 24160847
Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.
Siebert U, Jahn B, Rochau U, Schnell-Inderst P, Kisser A, Hunger T, Sroczynski G, Mühlberger N, Willenbacher W, Schnaiter S, Endel G, Huber L, Gastl G; Oncotyrol HTA & Outcomes Research Working Group. Siebert U, et al. Among authors: gastl g. Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):330-40. doi: 10.1016/j.zefq.2015.06.012. Epub 2015 Jul 28. Z Evid Fortbild Qual Gesundhwes. 2015. PMID: 26354133
Current treatment concepts of Philadelphia-negative MPN.
Wolf D, Rudzki J, Gastl G. Wolf D, et al. Among authors: gastl g. Curr Cancer Drug Targets. 2011 Jan;11(1):44-55. doi: 10.2174/156800911793743592. Curr Cancer Drug Targets. 2011. PMID: 21062242 Review.
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
Petzer AL, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Stanchev A, Grubinger T, Kwakkelstein M, Schuld P, Gastl G, Wolf D. Petzer AL, et al. Among authors: gastl g. Haematologica. 2012 Oct;97(10):1562-9. doi: 10.3324/haematol.2011.060087. Epub 2012 Apr 17. Haematologica. 2012. PMID: 22511495 Free PMC article. Clinical Trial.
The kinase inhibitor imatinib--an immunosuppressive drug?
Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM. Wolf D, et al. Among authors: gastl g. Curr Cancer Drug Targets. 2007 May;7(3):251-8. doi: 10.2174/156800907780618293. Curr Cancer Drug Targets. 2007. PMID: 17504122 Review.
295 results